Starting next week, we’ll be sending our newsletter on Wednesdays instead of Fridays.
Hopefully some fun facts about drugs will help you get through the week!
Here’s what’s in store for you in today’s issue:
🍄 Your chance to meet Paul Stamets
🍄 How psilocybin could make industrial farming less cruel 🐄
🍄 The intense psychedelic that could help new moms
🍄 Health Canada approves psilocybin SAP request for first time 🎉
🍄 And more.
In this episode of the Daily Mushroom podcast, we have Dr. Pam Kryskow, a psychedelic researcher, medical doctor, and the medical lead for ketamine-assisted therapy for the Roots to Thrive program. Pam shares the benefits of psychedelic therapy in group settings and how her hiking “trips” helped her cope with daily trauma experienced in her previous job as a firefighter.
|
MAPS celebrates bday with 30,000 doses of MDMAMAPS developed the first validated method of synthesizing MDMA on an industrial scale while meeting Good Manufacturing Practices. And better yet, they are placing the process in the public domain to promote scientific advances and patient access. The 4-step process produces up to 5 kg of MDMA (or roughly 30,000 doses) with 99.9% purity. With MDMA expected to be FDA-approved next year, this advancement comes at the perfect time to meet the growing demand for the drug 👏 Today is MAPS’ 36th birthday 🥳 See all that the org has accomplished here. |
Here’s something to ponder on your next trip…A new Johns Hopkins study found that mystical psychedelic experiences are linked to changes in peoples’ beliefs about consciousness. After a single psychedelic experience, people were much more likely to attribute consciousness to animals, insects, fungi, plants, and even inanimate objects. However, psychedelics had no effect on beliefs about free will or superstition. What do you think — do mushrooms have consciousness? |
The most intense psychedelic could be perfect for new moms!Field Trip Health (FTRP) was granted a US patent for its formulation of 4-HO-DiPT (aka Isoprocin Glutarate), an extremely intense psychedelic lasting 2-3 hours. Field Trip will begin a Phase I safety trial within 3 months with hopes that it will lead to Phase II trials on treatment-resistant depression and postpartum depression. |
Beckley Psytech is running Phase I trials to compare two forms of 5-MeO-DMT: a dry powder nasal spray and a liquid nasal spray. The findings will determine which formulation will be used in an upcoming Phase II trial for treatment resistant depression.
Blackhawk Growth (BLR) entered into an agreement to acquire Blum Distributors, a mushroom supplier and cultivator, to reduce intermediaries in its supply chain.
Homecoming, a patient care platform that partners with psychedelic clinics, therapists, and retreats to support clients’ healing journeys, closed a $4M seed funding round.
Six patients with end-of-life distress received approval for psilocybin therapy through the Special Access Program (SAP), marking the first successful request since the program was amended in January.
The patients attended a group therapy workshop with Roots to Thrive using synthetic psilocybin that was generously donated by Psygen Labs and Apex Labs 
Among the six patients was Thomas Hartle, the first Canadian to receive a Section 56 exemption, allowing him to access psilocybin again, as the exemption expired after one year.
Learn how psilocybin has helped him in his battle with cancer on the Daily Mushroom Podcast – his story is so inspiring!
In some not-so-inspirational news, Canada will soon allow medical assistance in dying (MAID) for people with severe depression, bipolar disorder, personality disorders, schizophrenia, PTSD, or any other mental health condition that is deemed impossible to cure.
Maybe if psychedelic therapy was more accessible, patients wouldn’t have to resort to assisted suicide. Help us change this 👇
|
|
